Coherus Oncology files to sell up to $50 million in stock through Leerink Partners
The August 28, 2026 prospectus supplement sets up an at-the-market equity program with no fixed timeline or minimum sales amount.
SEC filing
Latest
4 stories
Friday, September 25
Friday, August 28
Monday, August 17
Coherus Oncology refinances debt with new $55 million term loan
Coherus signed a new senior secured term loan facility on August 12, 2026, and used the proceeds to repay and terminate its prior loan agreement.
SEC filing
Wednesday, August 5
Coherus reports Q2 2026 results, flags October data update for tagmokitug
Coherus said LOQTORZI revenue rose 15% sequentially as it pointed to October for more mature clinical data on its CCR8 antibody in head and neck cancer.
SEC filing